Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook
NEW YORK, Jan 4, 2026, 13:54 ET — Market closed Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing The move matters because Ironwood is trying to prove it can generate steady cash flow from a single commercial asset while it works through a strategic review and prepares a key late-stage study for its pipeline drug apraglutide. SEC It also lands at a sensitive moment for U.S. drug pricing, where headline list-price cuts do not